Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.81 |
| ▸ | DRD2 | P14416 | 16/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2851449 | 0.99 | DRD3 (0.80) | DRD3KCNH2DRD2CYP1A2CYP2D6 | |
| SCHEMBL378314 | 0.90 | KCNH2 (0.84) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL378313 | 0.89 | KCNH2 (0.83) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL378352 | 0.88 | DRD3 (1.00) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL378168 | 0.87 | DRD3 (1.00) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL397107 | 0.87 | DRD3 (0.98) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL378874 | 0.87 | DRD3 (0.98) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL12313324 | 0.86 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL11911836 | 0.86 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL11915313 | 0.86 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803820-B2 | 3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | claimed |
| EP-1869018-B1 | 3-TRIAZOLYLTHIOALKYL-3-AZABICYCLO (3 - 1 - O) HEXANES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2010-01-13 | — | — | EP | claimed |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | claimed |
| EP-1869018-A1 | 3-TRIAZOLYLTHIOALKYL-3-AZABICYCLO (3 - 1 - O) HEXANES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | claimed |
| WO-2006108700-A1 | 3-TRIAZOLYLTHIOALKYL-3-AZABICYCLO (3 - 1 - O) HEXANES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
| US-7803820-B2 | 3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803820-B2 | 3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803820-B2 | 3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| EP-1869018-B1 | 3-TRIAZOLYLTHIOALKYL-3-AZABICYCLO (3 - 1 - O) HEXANES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | DRD3, HTR3C, HTR5A | DRD3 1/4885KCNH2 871/4885DRD2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.